Stimunity develops STING pathway agonists using enveloped virus-like particles (VLPs) to activate the innate immune system against cancer and infectious diseases. This approach enhances tumor antigen presentation and enables systemic administration, addressing the limited efficacy of existing immunotherapies that only benefit a small percentage of patients.
Funding
$972.9K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current immuno-oncology therapies, such as immune checkpoint inhibitors (ICIs), are only effective in a limited subset of patients with advanced or metastatic cancer. There is a need for novel drugs that can enhance the innate immune response and improve the efficacy of existing immunotherapies.
Solution
Stimunity is developing enveloped virus-like particle (VLP)-based STING agonists to activate the innate immune system and enhance anti-tumor immunity. Their approach leverages VLPs to deliver STING agonists preferentially to dendritic cells, improving tumor antigen presentation and avoiding cell-specific side effects. This VLP-based delivery system enables systemic administration, unlocking the possibility of multiple rounds of treatment and therapeutic use across various tumor indications, unlike first-generation STING agonists limited to intratumoral administration. By stimulating a potent and specific T cell response against tumor cells, Stimunity's STING agonists aim to improve outcomes for patients who do not respond to conventional immunotherapies and restore ICI efficacy when used in combination.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and clinical investigators focused on developing novel immuno-oncology therapies and improving treatment outcomes for cancer patients.
Features
- Enveloped virus-like particle (VLP) platform for targeted delivery of STING agonists
- Preferential targeting of dendritic cells to enhance tumor antigen presentation
- Systemic administration route for broad therapeutic application
- STING activation to drive a potent and specific T cell response against tumor cells
- Potential to restore efficacy of immune checkpoint inhibitors (ICIs) in combination therapy